Evidence in Advanced Disease: The Challenge for New Therapies

Polascik, 1999, Prostate specific antigen: A decade of discovery—what we have learned and where we are going, J. Urol., 162, 293, 10.1016/S0022-5347(05)68543-6 Ornstein, 2000, Prostate-specific antigen, Expert Opin. Pharmacother., 1, 1399, 10.1517/14656566.1.7.1399 Cookson, 2001, Prostate cancer: Screening and early detection, Cancer Control, 8, 133, 10.1177/107327480100800203 Rietbergen, 1999, The changing pattern of prostate cancer at the time of diagnosis: Characteristics of screen detected prostate cancer in a population based screening study, J. Urol., 161, 1192, 10.1016/S0022-5347(01)61630-6 Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: International comparisons. Br J Urol Int 2002;90:162–73. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: Individual countries. Br J Urol Int 2002;90:174–84. Schröder, 2000, Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?, Prostate, 42, 107, 10.1002/(SICI)1097-0045(20000201)42:2<107::AID-PROS4>3.0.CO;2-E Schröder, 1997, Phase II studies on prostate cancer, Urology, 49, 3, 10.1016/S0090-4295(97)00160-X Tannock, 1996, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points, J. Clin. Oncol., 14, 1756, 10.1200/JCO.1996.14.6.1756 Kadmon, 1996, Pitfalls in interpreting prostate specific antigen velocity, J. Urol., 155, 1655, 10.1016/S0022-5347(01)66154-8 Thalmann, 1996, Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer, J. Natl. Cancer Inst., 88, 794, 10.1093/jnci/88.12.794 Dijkman, 1997, Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group, J. Urol., 158, 160, 10.1097/00005392-199707000-00051 Davidson, 1995, Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group, J. Urol., 154, 2118, 10.1016/S0022-5347(01)66711-9 Dowling, 2001, A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer, Ann. Oncol., 12, 773, 10.1023/A:1011116626590 Storlie, 1995, Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma, Cancer, 76, 96, 10.1002/1097-0142(19950701)76:1<96::AID-CNCR2820760114>3.0.CO;2-E Scher, 1999, Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer, J. Natl. Cancer Inst., 91, 244, 10.1093/jnci/91.3.244 Small, 2001, Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival, J. Clin. Oncol., 19, 1304, 10.1200/JCO.2001.19.5.1304 Bubley, 1999, Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group, J. Clin. Oncol., 17, 3461, 10.1200/JCO.1999.17.11.3461 Baselga J, Yano S, Giaccone G, Nakagawa K, Tamura T, Douillard J, et al. Initial results from a Phase II trial of ZD1839 (‘Iressa’) as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1). Clin Cancer Res 2001;7(Suppl):[Abstract 630A]. Blackledge, 2000, Anti-EGF receptor therapy, Prost. Cancer Prost. Dis., 3, 296, 10.1038/sj.pcan.4500488 Baselga J, LoRusso P, Herbst R, Rischin D, Ranson M, Maddox A-M, Averbuch S. A pharmacokinetic/pharmacodynamic trial of ZD1839 (‘Iressa’), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with 5 selected tumor types (a Phase I/II trial of continuous once-daily treatment). Clin Cancer Res 1999;5(Suppl):[Abstract 29]. Carducci, 2001, The endothelin-A receptor antagonist Atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: A multinational, randomized, double-blind, placebo-controlled trial, Proc. Am. Soc. Clin. Oncol., 20, 174a Nelson, 2001, The endothelin-A receptor antagonist Atrasentan (ABT-627) reduces skeletal remodeling activity in men with advanced, hormone refractory prostate cancer, Proc. Am. Soc. Clin. Oncol., 20, 4a